###begin article-title 0
###xml 100 122 100 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 100 121 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 35 57 35 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb</italic>
###xml 327 341 327 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 35 56 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 327 340 <span type="species:ncbi:5833">P. falciparum</span>
In vitro and in vivo resistance of Plasmodium falciparum to atovaquone or atovaquone-proguanil hydrochloride combination has been associated to two point mutations in the parasite cytochrome b (cytb) gene (Tyr268Ser and Tyr268Asn). However, little is known about the prevalence of codon-268 mutations in natural populations of P. falciparum without previous exposure to the drug in Africa.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 66 80 66 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 256 270 256 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 66 79 <span type="species:ncbi:5833">P. falciparum</span>
###xml 256 269 <span type="species:ncbi:5833">P. falciparum</span>
The prevalence of codon-268 mutations in the cytb gene of African P. falciparum isolates from Nigeria, Malawi and Senegal, where atovaquone-proguanil has not been introduced for treatment of malaria was assessed. Genotyping of the cytb gene in isolates of P. falciparum was performed by PCR-restriction fragment length polymorphism and confirmed by sequencing.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 299 313 299 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 299 312 <span type="species:ncbi:5833">P. falciparum</span>
295 samples from Nigeria (111), Malawi (91) and Senegal (93) were successfully analyzed for detection of either mutant Tyr268Ser or Tyr268Asn. No case of Ser268 or Asn268 was detected in cytb gene of parasites from Malawi or Senegal. However, Asn268 was detected in five out of 111 (4.5%) unexposed P. falciparum isolates from Nigeria. In addition, one out of these five mutant Asn268 isolates showed an additional cytb mutation leading to a Pro266Thr substitution inside the ubiquinone reduction site.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 42 56 42 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 173 187 173 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 237 251 237 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 377 391 377 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 42 55 <span type="species:ncbi:5833">P. falciparum</span>
###xml 173 186 <span type="species:ncbi:5833">P. falciparum</span>
###xml 237 250 <span type="species:ncbi:5833">P. falciparum</span>
###xml 377 390 <span type="species:ncbi:5833">P. falciparum</span>
No Tyr268Ser mutation is found in cytb of P. falciparum isolates from Nigeria, Malawi or Senegal. This study reports for the first time cytb Tyr268Asn mutation in unexposed P. falciparum isolates from Nigeria. The emergence in Africa of P. falciparum isolates with cytb Tyr268Asn mutation is a matter of serious concern. Continuous monitoring of atovaquone-proguanil resistant P. falciparum in Africa is warranted for the rational use of this new antimalarial drug, especially in non-immune travelers.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 51 73 51 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 191 205 191 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 625 636 625 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium </italic>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 712 714 712 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bc</italic>
###xml 717 723 717 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytbc1</italic>
###xml 734 735 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 839 850 839 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium </italic>
###xml 874 887 874 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 970 971 970 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 972 973 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1240 1243 1240 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1453 1455 1451 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1621 1622 1619 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1623 1625 1621 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1626 1628 1624 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1787 1789 1785 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1839 1841 1837 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2030 2035 2028 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 2036 2038 2034 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2039 2041 2037 2039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2239 2241 2237 2239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 2242 2244 2240 2242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2245 2247 2243 2245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2248 2250 2246 2248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2403 2417 2401 2415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 2431 2436 2429 2434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 2479 2481 2477 2479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 2482 2484 2480 2482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2485 2487 2483 2485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2488 2490 2486 2488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2491 2493 2489 2491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 51 72 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 191 204 <span type="species:ncbi:5833">P. falciparum</span>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 874 887 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1777 1785 <span type="species:ncbi:9606">children</span>
###xml 2308 2316 <span type="species:ncbi:9606">patients</span>
###xml 2403 2416 <span type="species:ncbi:5833">P. falciparum</span>
The rapid development and spread of drug resistant Plasmodium falciparum is a serious global health problem in the management of malaria infections. Increasing resistance to antimalarials by P. falciparum has led to renewed search for alternative effective new drugs with unique cellular targets. In the 1990s, the urgent need for new anti-malarial drugs for treatment and chemoprophylaxis led to the development of atovaquone (2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-hydroxynaphtoquinone)[1]. This anti-malarial compound has broad spectrum activity against human protozoan pathogens [2,3] among which are the Plasmodium spp. [4,5]. Atovaquone is a potent and specific inhibitor of the cytochrome bc1 (cytbc1) complex [6,7], an essential respiratory enzyme present in the inner mitochondrial membrane. Unfortunately, in the Plasmodium genus and especially in P. falciparum, atovaquone when used as a single agent showed a high frequency of recrudescence [8,9] and recrudescing parasites are approximately 1,000-10,000 fold more resistant [10-12]. In order to minimize the risk of resistance development, a fixed synergistic combination of atovaquone with proguanil hydrochloride was developed under the trade name of Malarone(R). It has been suggested that proguanil at lower doses acts synergistically to enhance the ability of atovaquone to collapse the mitochondrial membrane potential without affecting electron transport inhibition [13]. However, the exact mechanism of synergy between these two drugs remains unknown. The combination of atovaquone-proguanil (AP) can achieve a cure rate of 99%-100% [9,14-16]. Despite its high activity against the malaria parasite, the cost of AP treatment has until now restricted its use to western non-immune adult and children [17] travelers and some European military personnel [18]. Unfortunately, there is growing evidence that malaria parasites may quickly develop resistance to AP by mutation of amino acid residues located in or near the atovaquone-binding site on cytb [19-23]. Only a decade after its introduction, AP treatment failures have been reported in non-immune travelers returning from Africa. Nearly all cases are from individuals who have visited West Africa. [11,22,24-27]. AP treatment failures in a significant number of these patients have been genetically linked to point mutations in the atovaquone-binding site of the P. falciparum mitochondrial cytb gene(Tyr268Ser or Tyr268Asn or Tyr268Cys) [11,12,22,24-28].
###end p 11
###begin p 12
###xml 32 33 32 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 69 94 69 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae </italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb </italic>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 69 93 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Recently, Kessl and colleagues [7] used site directed mutagenesis in Saccharomyces cerevisiae to genetically and biochemically confirm the linkage of atovaquone/AP resistance to cytb mutations (Tyr268Ser and Tyr268Asn) and to explain at the molecular level the mechanism of malaria parasites resistance to this drug. Cytb Tyr268Ser and Tyr268Asn mutations, have been used as a potential molecular marker of AP resistance in non-immune travelers who present with malaria after visiting disease endemic areas [11,12,22,24-30].
###end p 12
###begin p 13
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 217 231 217 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 405 419 405 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 541 555 541 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 217 230 <span type="species:ncbi:5833">P. falciparum</span>
###xml 405 418 <span type="species:ncbi:5833">P. falciparum</span>
###xml 541 554 <span type="species:ncbi:5833">P. falciparum</span>
It has been suggested that AP resistant phenotypes might arise through strong selection of resistant sub-populations harboring resistance associated mutations [12,29] or, through a mutagenic capacity of atovaquone on P. falciparum parasites alone or even in the AP combination [19,20,25] However, very little is known on the background/baseline prevalence of codon-268 mutations in natural populations of P. falciparum without previous exposure to the drug in Africa. In this study, the prevalence of codon-268 mutations in the cytb gene of P. falciparum isolates from Nigeria, Malawi and Senegal was assessed.
###end p 13
###begin p 14
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 52 66 52 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 196 210 196 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 277 291 277 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 52 65 <span type="species:ncbi:5833">P. falciparum</span>
###xml 196 209 <span type="species:ncbi:5833">P. falciparum</span>
###xml 277 290 <span type="species:ncbi:5833">P. falciparum</span>
Although, no Tyr268Ser mutation is found in cytb of P. falciparum isolates from Nigeria, Malawi or Senegal, the presence of the cytb Tyr268Asn mutation is reported for the first time in unexposed P. falciparum isolates from Nigeria. The emergence of cytb Tyr268Asn mutation in P. falciparum populations of Africa is a matter of serious concern, since the AP combination has not been widely used yet in West Africa.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Study areas
###end title 16
###begin p 17
The studies were conducted at the Malaria Research Laboratory, College of Medicine, University of Ibadan, Nigeria (2003-2005), the Queen Elizabeth Central Hospital (within the Blantyre Malaria Project), University of Malawi College of Medicine, Blantyre, Malawi (1996-2005) and the Malaria Research Laboratory, Hopital Le Dantec, Dakar, Senegal (2002-2005).
###end p 17
###begin p 18
###xml 4 9 <span type="species:ncbi:9606">Human</span>
The Human Subjects Committee of Harvard School of Public Health in Boston, the Institutional Review Committees at the University of Ibadan, Ibadan, Nigeria, the ethical review committee at the College of Medicine, University of Blantyre, Malawi and the Ethics Committee of the Senegalese Ministry of Health approved the protocols used in these studies. Documented informed consent was obtained from parents/guardians.
###end p 18
###begin title 19
Biological materials
###end title 19
###begin p 20
###xml 50 54 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 135 148 133 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 325 330 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhfr </italic>
###xml 334 339 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 349 357 347 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 395 397 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 95 103 <span type="species:ncbi:9606">children</span>
###xml 135 148 <span type="species:ncbi:5833">P. falciparum</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
Peripheral blood samples preserved on 3 MM Whatman(R) filter paper were obtained from Nigerian children with microscopically confirmed P. falciparum. Parasites DNA samples from Nigerian patients used in this study are the same with those reported in a previous study describing the association between mutations in parasites dhfr and dhps genes and in vivo sulfadoxine-pyrimethamine resistance [31].
###end p 20
###begin p 21
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 165 176 <span type="species:ncbi:9606">participant</span>
Samples from Senegal were collected from patients attending a health clinic in Pikine, a suburb of the capital city, Dakar. A drop of blood obtained from each study participant at enrollment was blotted unto filter paper (ISOCODE, Schleicher & Schuell). The samples were air dried and stored in plastic bags containing silica gel.
###end p 21
###begin p 22
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 228 235 <span type="species:ncbi:9606">infants</span>
In Malawi, parasite DNA was obtained from either an archive of material collected from 1996 to 2004 or as part of an ongoing study of genetic diversity from 2003 to the present. Samples were collected from patients ranging from infants through adult with a spectrum of clinical disease from asymptomatic carriage to severe disease although this information was not used for analysis (i.e., the 91 samples represent the "population" of parasites for Malawi). All samples were either exempt from consent (archived parasite DNA previously extracted and stored at -80degreesC) or consented for collection of parasite DNA (fresh samples of peripheral blood extracted and stored at -80degreesC).
###end p 22
###begin title 23
DNA Extraction and PCR-RFLP for detection of codon-268 mutations in the cytb gene
###end title 23
###begin p 24
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 269 283 263 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 297 302 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 480 484 474 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 490 494 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 570 574 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 576 580 570 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 583 587 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 589 593 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 599 603 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 605 609 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 830 832 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 269 282 <span type="species:ncbi:5833">P. falciparum</span>
Parasite genomic DNA was extracted from blood samples collected on filter paper using the chelex extraction method as described by Plowe and others[32]. Part of the DNA extracted from each sample was used immediately for PCR and the rest was stored at -20degreesC. The P. falciparum mitochondrial cytb gene (GenBank accession no. ) was amplified by nested polymerase chain reaction and analyzed by restriction fragment length polymorphisms (RFLP). A nested PCR was designed using Cytb1 and Cytb2 as primary amplification primers and 3 different pairs of nested primers (Cytb2/Cytb6, Cytb2/Cytb7 and Cytb3/Cytb5) to distinguish the 3 known polymorphisms at codon 268 (Tyr268, Ser268 and Asn268). Primers sequences, primary and nested PCR conditions and procedures were performed as described previously by Schwobel and colleagues [25]. The product of each second round PCR was electrophoresed on 2% agarose gel and visualized under UV transillumination following staining with ethidium bromide.
###end p 24
###begin p 25
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 323 327 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
RLFP analysis of each cytb secondary amplification product was performed by digesting 5 muL of each PCR product with the appropriate restriction enzyme and its buffer in a total volume 15 muL and incubated at 37degreesC over night. The result was detected by electrophoresis in ethidium bromide-stained agarose gel (NuSieve(R) 3:1, Cambrex Bioscience Rockland Inc, ME, USA).
###end p 25
###begin p 26
###xml 129 133 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 135 139 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 187 192 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NsiI </italic>
###xml 446 450 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 452 456 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 493 499 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AlwNI </italic>
###xml 535 541 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AlwNI </italic>
###xml 737 741 734 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 743 747 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cytb</italic>
###xml 761 766 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SspI </italic>
###xml 915 929 912 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 915 928 <span type="species:ncbi:5833">P. falciparum</span>
For detection of the wild-type Tyr268 allele at position 268, 5 muL of the secondary amplification product using the primer pair Cytb3/Cytb5, was mixed with 1 U of the restriction enzyme NsiI (New England Biolabs, Beverly, MA). The enzyme cuts the wild-type allele (Tyr268) and mutant Asn268 but not the mutant Ser268 allele. Detection of mutant Ser268 allele was performed by digesting 5 muL of the 171 bp region amplified using the primer pair Cytb2/Cytb2 with 1 U of the restriction enzyme AlwNI (New England Biolabs, Beverly, MA). AlwNI cuts the mutant Ser268 allele but not the wild-type Tyr268 or the mutant Asn268 allele. The mutant Asn268 allele was detected by mixing 5 muL of the secondary amplification product (174 bp) using Cytb2/Cytb7 with 1 U of SspI (New England Biolabs, Beverly, MA). The enzyme cuts the wild-type Tyr268 allele or the mutant Ser268 allele but not the mutant Asn268 allele. DNA of P. falciparum clones 3D7 (Tyr268 allele), K1 (Tyr268 allele) and NGATV0l (Asn268 allele) strain were used as controls.
###end p 26
###begin title 27
Clonal analysis of PCR products and DNA sequencing
###end title 27
###begin p 28
###xml 46 50 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 58 66 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 108 115 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 517 522 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 852 854 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 903 917 883 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 108 115 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 903 916 <span type="species:ncbi:5833">P. falciparum</span>
PCR amplified products were cloned into TopoTA(R) vector (In vitrogene, San Diego, CA) and transfected into E. coli. Cells were grown overnight in terrific broth and Plasmid DNA was isolated using the SNAP Gel Purification Kit (Invitrogen, Carlsbad, CA). Samples of plasmid DNA containing inserts of interest were purified using a QIAprep Spin Plasmid Kit, and then sequenced using ABI PRISM Big dye Terminator Kit at a commercial facility (Dana Farber Cancer Research Institute, Harvard University, Boston, MA). The cytb coding region of mitochondrial DNA from each clone was sequenced five times in both the forward and reverse direction using the vector primers M13 forward and M13 reverse. DNA and protein sequences alignment was performed using the SeqMantrade mark and MegAligntrade mark (Seqwright, Houston, TX; DNASTAR, Madison WI) and MUSCLE [33] protein multiple sequence alignment softwares. P. falciparum clones 3D7 (Tyr268 allele), K1 (Tyr268 allele) and NGATV0l (Asn268 allele) strain were used as controls.
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 354 361 <span type="species:ncbi:9606">patient</span>
###xml 444 452 <span type="species:ncbi:9606">Patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
A total of 309 samples were obtained from patients in Nigeria (118), Malawi (93) and Senegal (98). Out these samples, 295 (Nigeria 111; Malawi 91 and Senegal 93) were successfully tested for two different mutations on codon 268 of the parasite's cytb gene, which has been associated previously with AP treatment failure [12,20,22-27]. Seven (7), 2 and 3 patient samples from Nigeria, Malawi and Senegal respectively did not yield PCR products. Patients characteristics are presented in Table 1. All patients were Africans resident of malaria endemic areas of West Africa (Nigeria and Senegal) and East Africa (Malawi) where AP is neither used for chemoprophylaxis nor for treatment of malaria.
###end p 30
###begin p 31
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients from whom samples were used for detection of cytb mutations at codon 268.
###end p 31
###begin p 32
###xml 66 80 66 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 66 79 <span type="species:ncbi:5833">P. falciparum</span>
In the parasite populations studied, PCR-RFLP results revealed no P. falciparum isolate from Nigeria, Senegal or Malawi with the mutant Ser268 allele in the cytb gene. All isolates from Senegal and Malawi harboured the wild-type cytb Tyr268 allele. In addition, none of the isolates obtained from these 2 study sites showed the mutant cytb Asn268 allele.
###end p 32
###begin p 33
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 772 773 772 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Surprisingly, five isolates out of the 111 samples obtained from Nigerian patients showed the mutant cytb Asn268 allele. The resulting pattern after restriction enzyme digest of some of these five samples is shown in Figure 1. SspI cut the 174 bp product of the nested PCR into two fragments (150 bp and 24 bp) in presence of the TAT (Tyr) wild-type codon, while the mutant AAT (Asn) codon remained uncut. Fragment sizes between the wild-type cytb Tyr268 and mutant cytb Asn268 differed by 24 bp (Figure 1). One (1) out of the five (5) samples that revealed the mutant Asn 268, showed a mixed (Tyr268 and Asn268) pattern, consisting of wild-type and mutant alleles at codon 268. The presence of these mutations was further confirmed by sequencing. Sequencing data (Figure 2) confirmed the presence of the Asn268 mutation in all the five samples from which the mutant alleles were detected by RFLP.
###end p 33
###begin p 34
###xml 53 67 53 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb</italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb</italic>
###xml 267 271 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 689 694 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 53 66 <span type="species:ncbi:5833">P. falciparum</span>
###xml 476 483 <span type="species:ncbi:9606">patient</span>
###xml 621 628 <span type="species:ncbi:9606">Patient</span>
Detection of Asn268 mutation in cytochrome b gene in P. falciparum by Restriction digest method. 174 bp amplification products with the secondary amplification primer pair cytb2/cytb7 (lanes 3, 5, 7, 9) digested with SspI (lanes 2, 4, 6, 8) and were run on 2% NuSieve(R) 3:1 agarose gel. DNA from NGATV01 containing the AAT (Asn) mutation remains uncut (lane 6), while DNA from K1 containing the TAT (Tyr) wild-type codon is digested (150 bp) by the enzyme (lane 8). DNA from patient ID011 showed a mixed infection consisting both the TAT (Tyr) wild-type digested (150 bp) and mutant undigested (174 bp) codons (lane 2). Patient ID024 had parasites harboring the mutant (Asn268) allele of cytb as their DNA remained uncut (lane 4) by the enzyme. Lanes 1 and 10 represent the low molecular weight DNA ladder (New England Biolabs, Beverly, MA) used as a marker for the electrophoresis
###end p 34
###begin p 35
###xml 101 114 101 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 289 310 289 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 101 114 <span type="species:ncbi:5833">P. falciparum</span>
###xml 289 310 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 339 346 <span type="species:ncbi:9606">patient</span>
Multiple sequences alignment of cytochrome b gene (residues 137 to 279) of some Nigerian isolates of P. falciparum. Highlighted are residues 268 with amino acid changes from the wild-type tyrosine (Y) to the mutant asparagine (N) allele associated previously with atovaquone resistance in Plasmodium falciparum. In addition residue 266 in patient ID (Cytb012) where Pro (P) is changed to Thr (T) is also highlighted. Sequences of the atovaquone resistant (NGTV01) and sensitive (K1 and 3D7) control strains are also present.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 91 110 91 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum cytb </italic>
###xml 236 250 236 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 387 401 387 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 91 104 <span type="species:ncbi:5833">P. falciparum</span>
###xml 236 249 <span type="species:ncbi:5833">P. falciparum</span>
###xml 387 400 <span type="species:ncbi:5833">P. falciparum</span>
In this study, the background/baseline prevalence of AP associated resistance mutations in P. falciparum cytb gene in isolates from three distinct geographical areas of Africa where the drug has not been introduced for the treatment of P. falciparum malaria was determined. The data from the study provides the very first evidence of the presence of cytb Tyr268Asn mutation in unexposed P. falciparum isolates from Africa.
###end p 37
###begin p 38
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 189 203 189 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 314 317 314 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 520 533 520 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 571 576 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 781 795 781 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 189 202 <span type="species:ncbi:5833">P. falciparum</span>
###xml 221 228 <span type="species:ncbi:9606">patient</span>
###xml 450 457 <span type="species:ncbi:9606">patient</span>
###xml 520 533 <span type="species:ncbi:5833">P. falciparum</span>
###xml 781 794 <span type="species:ncbi:5833">P. falciparum</span>
In 2002, the first case of in vivo resistance to AP was reported in a non-immune European traveler returning from Nigeria [22]. Molecular and phenotypic characterizations of the isolate of P. falciparum obtained from the patient showed a Tyr to Asn mutation at codon 268, resulting in a 800 fold increase of the IC50 [22]. However, Fivelman and colleagues [22] argued that since AP combination is not yet used in West Africa, it is unlikely that the patient was initially infected with an atovaquone resistant strain of P. falciparum. Thus, the mutation in the parasites cytb gene would have occurred under AP pressure. The data from this study is contradictory to the argument raised by Fivelman and colleagues [22], since AP combination is still not used in Nigeria and yet some P. falciparum from the same locality harbor mutant Asn268 allele.
###end p 38
###begin p 39
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 88 102 88 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 229 243 229 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 396 417 396 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pneumocystis carinii </italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb</italic>
###xml 686 700 686 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 912 933 912 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pneumocystis carinii </italic>
###xml 88 101 <span type="species:ncbi:5833">P. falciparum</span>
###xml 229 242 <span type="species:ncbi:5833">P. falciparum</span>
###xml 396 416 <span type="species:ncbi:4754">Pneumocystis carinii</span>
###xml 430 433 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 686 699 <span type="species:ncbi:5833">P. falciparum</span>
###xml 730 733 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
###xml 912 932 <span type="species:ncbi:4754">Pneumocystis carinii</span>
The reasons behind the emergence of the mutant Asn268 allele of cytb gene is indigenous P. falciparum unexposed to AP combination is remain unclear. It has been suggested that the mutations at codon 268 of cytb gene in unexposed P. falciparum populations may occur either naturally [11] or through prior exposure to related drugs [27]. Trimethoprim-sulfametoxazole is often used for treatment of Pneumocystis carinii pneumonia in HIV patients in Nigeria. However, for patients who react to this sulfa-based combination, atovaquone is given as a rescue therapy. It is possible that treatment with atovaquone in this category of patients could select for mutant Asn cytb268 in indigenous P. falciparum population in this area where HIV patients could be co-infected with malaria, although there is no clear evidence of this selection process. A recent report [34] has shown that the percentage of individuals with Pneumocystis carinii pneumonia who are co-infected with other pathogens is very high (ranging from 20% to 70%) in Africa and other developing countries.
###end p 39
###begin p 40
###xml 51 65 51 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 439 452 439 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 51 64 <span type="species:ncbi:5833">P. falciparum</span>
###xml 439 452 <span type="species:ncbi:5833">P. falciparum</span>
Another potential explanation for the emergence of P. falciparum with cytb Asn268 mutation in Nigeria could be due to the selection of this allele by AP in the large number non-immune (European and Americans) workers (under AP chemoprophylaxis) in the Nigerian oil industry. Investigations are currently underway to determine if AP chemoprophylaxis among non-immune oil workers is exerting some selective pressure on indigenous strains of P. falciparum.
###end p 40
###begin p 41
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 68 82 68 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 213 227 213 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb </italic>
###xml 631 635 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytb</italic>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1247 1248 1247 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 68 81 <span type="species:ncbi:5833">P. falciparum</span>
###xml 213 226 <span type="species:ncbi:5833">P. falciparum</span>
The detection and confirmation of mutant cytb Asn268 allele in some P. falciparum isolates from Nigeria is a matter of serious concern since these parasites may spread to other neighboring African countries where P. falciparum resistance to atovaquone or AP combination has not been reported. Recent studies [7,12,22,23] confirmed genetically and biochemically the linkage of atovaquone/AP resistance to cytb mutations (Tyr268Ser and Tyr268Asn) and the molecular mechanisms of parasites resistance this drugs. Tyr268 is a conserved bulky hydrophobic contact of atovaquone in the Qo II region of the ubiquinol oxidation site of the cytbc1 complex. Substitution of Tyr268 by a less bulky Asn268 not only reduces the volume of the binding pocket, but also decreases the affinity and binding of atovaquone and thus leads to drug resistance [22,35]. Of interest, is the presence in one sample (Cytb012) of an addition mutation at position 266, where Pro (P) is substituted to Thr (T). The presence and the role of this mutation within the atovaquone binding site needs further investigation, as the presence of additional mutations within the ubiquinone reduction site has been previously suggested to be involved in high level resistance to the drug [7].
###end p 41
###begin p 42
###xml 141 155 141 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 141 154 <span type="species:ncbi:5833">P. falciparum</span>
Efforts are currently underway to conduct a more elaborate study where genotypic and phenotypic characterization of AP resistant isolates of P. falciparum will be determined especially in Nigeria.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 86 100 86 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 148 162 148 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 406 420 406 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 86 99 <span type="species:ncbi:5833">P. falciparum</span>
###xml 148 161 <span type="species:ncbi:5833">P. falciparum</span>
###xml 406 419 <span type="species:ncbi:5833">P. falciparum</span>
This study reports for the first time the presence of Tyr268Asn mutation in unexposed P. falciparum isolates from Nigeria. The emergence in African P. falciparum isolates of Tyr268Asn mutation which is associated with AP resistance raises serious concerns about the long-term use of this drug for malaria chemoprophylaxis in non-immune travelers visiting West Africa. Continuous monitoring of AP resistant P. falciparum in Africa is warranted for the rational use of this valuable antimalarial drug especially in non-immune travelers.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
###xml 155 163 <span type="species:ncbi:9606">patients</span>
HCT, GOG, OAF, AS, KED, MKW, WFD and AMJO contributed to the conception and design of the study. HCT, GOG, OAF, MD, OS and AS participated in enrolment of patients and sampling. HCT, GOG, OAF, MD, OS performed molecular typing of isolates and analysis of data. All the authors contributed to writing the manuscript. All the authors read and approved the final version that was submitted for publication.
###end p 46
###begin title 47
Disclaimer
###end title 47
###begin p 48
The opinions or assertions contained herein are the private views of the authors (MKW and KED), and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.
###end p 48
###begin title 49
Acknowledgements
###end title 49
###begin p 50
###xml 210 224 210 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 362 376 362 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 210 223 <span type="species:ncbi:5833">P. falciparum</span>
###xml 362 378 <span type="species:ncbi:5839">P. falciparum K1</span>
The authors thank all the patients, their parents/guardians for volunteering to participate in the studies. We thank Prof. David Warhurst at the London School of Hygiene and Tropical Medicine for providing the P. falciparum strain NGATV0l genomic DNA. We also thank the Malaria Research and Reference Reagent Resource Centre (MR4) for providing genomic DNA from P. falciparum K1 and 3D7 strains. This study was supported by a grant from the Fogarty International Centre (FIC/NIH), the Multilateral Initiative for Malaria in Africa (MIM)/TDR, the UNICEF/UNDP/World Bank/WHO/TDR, the Harvard Malaria Initiative and the International Atomic Energy Agency (IAEA). C.T Happi is supported by a Fogarty International Research Collaboration Award (FIRCA) no. NIH RO3TW006298-01A1, the IAEA project RAF/0625 and the WHO/TDR/PAG/South-South Initiative project ID A50337. GOG is supported by the MIM/TDR project ID A20239. OS is supported by the Fogarty International Research Training Grant TW01503-0. DM is supported by The American Society of Tropical Medicine and Hygiene Tropical Infectious Disease Fellowship provided for by the Burroughs Wellcome and Ellison Medical Foundations.
###end p 50
###begin article-title 51
Development of new drugs for chemoprophylaxis of malaria
###end article-title 51
###begin article-title 52
###xml 31 55 31 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Babesia gibsoni in vivo </italic>
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 31 46 <span type="species:ncbi:33632">Babesia gibsoni</span>
Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro
###end article-title 52
###begin article-title 53
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 119 136 119 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Toxoplasma gondii</italic>
###xml 119 136 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii
###end article-title 53
###begin article-title 54
Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)
###end article-title 54
###begin article-title 55
Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite
###end article-title 55
###begin article-title 56
Molecular basis for atovaquone binding to the cytochrome bc1 complex
###end article-title 56
###begin article-title 57
###xml 138 162 138 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 138 162 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae
###end article-title 57
###begin article-title 58
###xml 73 95 73 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 73 94 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria
###end article-title 58
###begin article-title 59
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
###end article-title 59
###begin article-title 60
Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group
###end article-title 60
###begin article-title 61
###xml 59 81 59 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 59 80 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers
###end article-title 61
###begin article-title 62
###xml 44 66 44 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 44 65 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations
###end article-title 62
###begin article-title 63
A mechanism for the synergistic antimalarial action of atovaquone and proguanil
###end article-title 63
###begin article-title 64
###xml 91 113 91 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 91 112 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 124 132 <span type="species:ncbi:9606">children</span>
Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children
###end article-title 64
###begin article-title 65
Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia
###end article-title 65
###begin article-title 66
###xml 117 139 117 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 117 138 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru
###end article-title 66
###begin article-title 67
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study
###end article-title 67
###begin article-title 68
The safety of atovaquone/proguanil in long-term malaria prophylaxis of non-immune adults
###end article-title 68
###begin article-title 69
Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites
###end article-title 69
###begin article-title 70
###xml 13 35 13 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 13 34 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site
###end article-title 70
###begin article-title 71
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum: the effects of atovaquone resistance on respiration
###end article-title 71
###begin article-title 72
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Malarone treatment failure and in vitro confirmationof resistance of Plasmodium falciparum isolate from Lagos, Nigeria
###end article-title 72
###begin article-title 73
###xml 53 62 53 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 164 185 164 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 164 185 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum
###end article-title 73
###begin article-title 74
###xml 12 34 12 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 12 33 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports
###end article-title 74
###begin article-title 75
###xml 56 87 56 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum in vitro </italic>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 176 184 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 56 77 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker
###end article-title 75
###begin article-title 76
Atovaquone/proguanil resistance in Africa: a case report
###end article-title 76
###begin article-title 77
###xml 65 87 65 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 65 86 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa
###end article-title 77
###begin article-title 78
###xml 120 142 120 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 120 141 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe
###end article-title 78
###begin article-title 79
###xml 36 40 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 75 97 73 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 75 96 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Detection of atovaquone and Malarone(R) resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb)
###end article-title 79
###begin article-title 80
###xml 69 91 69 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 69 90 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola
###end article-title 80
###begin article-title 81
###xml 17 44 17 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum dhfr </italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhps </italic>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 17 38 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria
###end article-title 81
###begin article-title 82
###xml 63 85 63 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 63 84 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa
###end article-title 82
###begin article-title 83
MUSCLE: multiple sequence alignment with high accuracy and high throughput
###end article-title 83
###begin article-title 84
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pneumocystis carinii </italic>
###xml 0 20 <span type="species:ncbi:4754">Pneumocystis carinii</span>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome
###end article-title 84
###begin article-title 85
Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone
###end article-title 85

